ALS TDI officially announced yesterday (Dec. 19, 2011) that an agreement has been reached with two major global pharmaceutical companies – Biogen Idec and UCB Pharma – to jointly investigate a potential treatment for ALS. Thanks to your past support, MDA’s Augie’s Quest has funded over $23.1 million to ALS TDI in the past 6 years, helping to make this breakthrough possible! You can read the full public announcement from TDI by clicking here.
“Steve Perrin and his team have been working diligently to make this historical partnership happen for months. Lynne and I consider this the best Christmas present we could ever ask for. This announcement means we are accomplishing what we set out to do at the beginning of our journey. We want to thank everyone at MDA, ALS TDI and most importantly our friends who have supported us and helped make this possible*.
“It is with great appreciation for the efforts of MDA’s Augie’s Quest that we make this exciting announcement. The support that ALS TDI has received from all those involved in Augie’s Quest have played a key role in moving our research forward. Without your help, we wouldn’t have been able to do the research necessary as quickly as we did in order to enter into this exciting research agreement with two global organizations. Thank you all for your trust and support.” – Steve Perrin, Ph.D., CEO & CSO of ALS TDI.
A webinar will be held on January 5, 2012 at 1PM (EST) to discuss this research effort. We encourage you to join us to learn more.
We hope you have a safe and healthy Holiday Season,
MDA’s Augie’s Quest